414 related articles for article (PubMed ID: 18573339)
21. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
22. Escape mechanisms in tumor immunity: an update.
Müller L; Kiessling R; Rees RC; Pawelec G
J Environ Pathol Toxicol Oncol; 2002; 21(4):277-330. PubMed ID: 12510961
[TBL] [Abstract][Full Text] [Related]
23. From cancer immunosurveillance to cancer immunotherapy.
Stagg J; Johnstone RW; Smyth MJ
Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
[TBL] [Abstract][Full Text] [Related]
24. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
25. Tumour-released exosomes and their implications in cancer immunity.
Iero M; Valenti R; Huber V; Filipazzi P; Parmiani G; Fais S; Rivoltini L
Cell Death Differ; 2008 Jan; 15(1):80-8. PubMed ID: 17932500
[TBL] [Abstract][Full Text] [Related]
26. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
27. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
29. Tumors and the danger model.
Kowalczyk DW
Acta Biochim Pol; 2002; 49(2):295-302. PubMed ID: 12362970
[TBL] [Abstract][Full Text] [Related]
30. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
Atreya I; Neurath MF
Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
32. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
33. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
[TBL] [Abstract][Full Text] [Related]
34. Introduction: the immune response against dying cells.
Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):501-3. PubMed ID: 18657612
[TBL] [Abstract][Full Text] [Related]
35. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
36. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
37. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.
Aymeric L; Apetoh L; Ghiringhelli F; Tesniere A; Martins I; Kroemer G; Smyth MJ; Zitvogel L
Cancer Res; 2010 Feb; 70(3):855-8. PubMed ID: 20086177
[TBL] [Abstract][Full Text] [Related]
38. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
40. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
Zhou Q; Guo AL; Xu CR; An SJ; Wang Z; Yang SQ; Wu YL
Clin Exp Immunol; 2008 Sep; 153(3):392-400. PubMed ID: 18803763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]